Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
Companies — both big and small — are hoping to grab a piece of the lucrative anti-obesity drug market. Piper Sandler counts 78 agents in development.
Source: cnbc.com